Compare RILYP & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RILYP | SCLXW |
|---|---|---|
| Founded | 1973 | N/A |
| Country | United States | United States |
| Employees | 1380 | 34 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | RILYP | SCLXW |
|---|---|---|
| Price | $13.18 | $0.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.6K | 6.0K |
| Earning Date | 01-01-0001 | 03-07-2025 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $854,383,000.00 | $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $3.25 | $0.05 |
| 52 Week High | $17.52 | $0.64 |
| Indicator | RILYP | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 28.56 | 49.27 |
| Support Level | $8.35 | $0.17 |
| Resistance Level | $14.50 | $0.21 |
| Average True Range (ATR) | 0.29 | 0.02 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 0.72 | 60.03 |
BRC Group Holdings Inc is a diversified holding company offering a platform of businesses, including financial services, telecom, retail, and investments in equity, debt, and venture capital. It serves retail, corporate, capital providers, and individual customers across various business lines. The Group has seven reportable business segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, UOL, and Consumer Products. Maximum revenue is generated from the Capital Markets segment, which provides investment banking and institutional brokerage services, offers loans, trades in equity securities, and maintains an investment portfolio of public and private equities and debt securities. Geographically, the Group derives maximum revenue from its business in North America.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.